Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 3, 2004, Pages 220-228

  Bartolomei, M ^a   Mazzetta, C ^a   Handkiewicz Junak, D ^a   Bodei, L ^a   Rocca, P ^a   Grana, C ^a   Maira, G ^b   Sturiale, C ^c   Villa, G ^a   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

Avidin; Biotin; Glioblastoma; Monoclonal antibodies; Radioimmunotherapy; Temozolomide

Indexed keywords

AVIDIN; BIOTIN; MONOCLONAL ANTIBODY; TEMOZOLOMIDE; UNCLASSIFIED DRUG; YTTERBIUM; YTTERBIUM 90;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYOCLONUS EPILEPSY; NEPHROTOXICITY; NEUROLOGIC DISEASE; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTIN; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; HUMANS; ITALY; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 8444251339     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasm. Neurology 1985;35: 219-26.
2. DeAngelus LM. Brain tumors. N Engl J Med 2001;344:114-23.
3. Brada M, Thomas GT. Tumors of the brain and spinal cord in adults. In: Peckham M, Pinedo H, Veronesi U, editors. Oxford Textbook of Oncology. New York: Oxford Medical Publications; 1995.p.2063-94.
4. Gregor A, Cull A. Radiotherapy for malignant glioma. BMJ 1996;313:1500-1.
5. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship on the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
6. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumour localization of 131I-labeled antitenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807-13.
7. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Fur J Nucl Med 1999;26:348-57.
8. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002;86:207-12.
9. 90Y-conjugates: the IEO experience. Q J Nucl Med 2000; 44:325-32.
10. 90Y: a Phase I study. Clin Cancer Res 1999;5 10 Suppl:3275s-80s.
11. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995;34:121-31.
12. Bigner DD, Brown M, Friedman AH, Coleman RE, Akabani G, Friedman HS et al. Iodine 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998;16:2202-12.
13. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE et al. Phase I trial results of Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-72.
14. Larson SM. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res 1990;50 3 Suppl:892s-8s.
15. Goodwin DA. Pharmacokinetics and antibodies. J. Nucl. Med 1987;28:1358-62.
16. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226-34.
17. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003;44:400-11.
18. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
19. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001;16:227-35.
20. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000; 27:601-7.
21. Zagzag D, Friedlander DR, Miller D, Dosik J, Cangiarella J, Kostianovsky M et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995;55:907-14.
22. Stupp R, Gardner M, Leyvraz S, Newlands E. Current and future developments in the use of Temozolomide for the treatment of brain tumors. Lancet Oncol 2001;2:552-60.
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
25. Therneau TM, Grambsch PM. Modelling Survival Data. New York: Springer; 2000.
26. Hochberg FH, Pruitt A. Assumption in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
27. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16:1405-9.
28. Burger PC, Dubois PJ, Schold SC Jr, Smith KR Jr, Odom GL, Crafts DC et al. Computerized tomography and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983;58:159-69.
29. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlation of computed tomography - and magnetic resonance imaging - defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-9.
30. Neider C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Results 2000;26: 397-409.
31. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65.
32. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175-82.
33. Boiardi A, Salmaggi A, Pozzi A, Broggi G, Silvani A. Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J Neurooncol 1996;27:157-62.
34. Enelhard HH. The role of interstitial BCNU chemotheraphy in the treatment of malignant glioma. Surg Neurol 2000;53:458-64.
35. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC et al. The Brain Tumor Cooperative Group NIH Trial 78-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002;51:343-55; discussion 355-7
36. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res 1998;18:1303-10.
37. Yung WKA, Albright RE, Olson J. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93.
38. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66.
39. Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R et al. Temozolomide as a second-line systematic regimen in recurrent high-grade glioma: A phase II study. Ann Oncol 2001;12:255-7.
40. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
41. Van Rijn J, Heimans JJ, Van der Berg J, Van der Valk P, Slotman BJ. Survival of glioma cells treated with various combination of Temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000; 47:779-84.
42. Qin DX, Zheng R, Tang J, Li J, Hu Y. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncolo Biol Phys 1990;19:1507-10.
43. Shepherd SF, Laing RW, Cosgrove VP Warrington AP, Hines F, Ashley SE et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 1997;37:393-8.
44. Mayr MT, Crocker IR, Butker EK, Williams H, Cotsonis GA, Olson JJ. Results of interstitial brachytherapy for malignant brain tumors. Int J Oncol 2002;2:817-23.
45. Collao C, de Tribolet N, Dietrich P-Y, Leyvraz S, Maeder P, Maillard I et al. Promising survival with concomitant and adjuvant Temozolomide for newly diagnosed glioblastoma multiforme. Proc An Soc Clin Oncol 2000;19:163a.